Drug intelligence / Profile preview

Danlu Capsule

Development stage: Unknown
Lead developer: Suzhong Pharmaceutical
Modality: Small Molecules
Administration: Oral

Overview

Danlu Capsule is a traditional Chinese herbal medicine developed by SZYY Group Pharmaceutical Ltd. It is indicated for the treatment of breast diseases, particularly breast hyperplasia. The drug has been approved in China since March 16, 2020, and its primary therapeutic areas are skin and musculoskeletal diseases. The mechanism of action and specific active ingredients have not been disclosed in public sources; as a herbal medicine, it likely contains multiple plant-derived compounds acting through various pathways relevant to its indications[1].

Brand names: Danlu Capsule
Other names: 丹鹿胶囊

Beyond the preview

Go deeper on Danlu Capsule.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Danlu Capsule.

Explore the full profile